
|Articles|July 1, 1999
Supplements and Featured Publications
- Evaluating the Health Benefits of Atypical Agents in the Treatment and Management of Psychoses
- Volume 5
- Issue 10 Suppl
Participating Faculty
Advertisement
Articles in this issue
over 26 years ago
Introductionover 26 years ago
Assessment of Quality-of-Life Outcomes in Schizophrenic Patientsover 26 years ago
The Emerging Role of Psychiatric Pharmacistsover 26 years ago
CME/CE Quizover 26 years ago
Selected Abstractsover 26 years ago
BibliographyNewsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA to Accept Deidentified Real-World Evidence for Select Medical Device Applications
2
ACA Subsidy Expiration Raises Concerns for Behavioral Health Access and ED Strain
3
HIV in 2025 Defined by Challenges Throughout the Year, Despite Some Advances
4
FDA Approves Intranasal Etripamil for Type of Arrhythmia
5









































